Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic lupus erythematosus
•
Pediatric Rheumatology
•
SLE
In patients with possible early SLE or undifferentiated disease can multiomics be used to help predict what disease phenotype they will develop?
Related Questions
Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
Where do you introduce SGLT2 and GLP1 medications in the sequence of treatments for patients with lupus nephritis?
What is your workup and treatment approach for cranial neuropathies in patients with lupus?
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
What factors drive you to prioritize treatments that inhibit T cells vs B cell depletion when choosing therapies for patients with refractory SLE?
For patients with SLE, is there an ANC level for which you would hold or adjust hydroxychloroquine in an asymptomatic patient?
How should rheumatologists address the impact on patients who are initially diagnosed with SLE based on positive ANA, but later reclassified as having UCTD?
Do you hospitalize patients with newly diagnosed lupus nephritis and nephrotic syndrome if you are able to provide pulse steroids outpatient and follow them closely?
How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?
